Kbi-092 -

They provide the necessary infrastructure—including mammalian and microbial expression systems —to ensure that experimental compounds like KBI-092 meet strict GMP (Good Manufacturing Practice) standards for human testing. Description Primary Code Drug Class Small molecule antineoplastic; Dual Kinase Inhibitor Targets FLT3 and IRAK4 Primary Indication Relapsed/Refractory Acute Myeloid Leukemia (RR-AML) Administration Oral tablet, twice daily (BID) Trial Phase Phase 1 (First-in-Human)

This protein is a central mediator in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. These pathways are frequently hijacked by cancer cells to promote inflammation and evade cell death, particularly in patients who have failed prior FLT3 inhibitor therapy. KBI-092

The drug has received clearance from both the FDA (United States) and the NMPA (China) to begin Phase 1 clinical trials. The drug has received clearance from both the